Literature DB >> 9482211

Regional, developmental, and cell cycle-dependent differences in mu, delta, and kappa-opioid receptor expression among cultured mouse astrocytes.

A Stiene-Martin1, R Zhou, K F Hauser.   

Abstract

The diversity of opioid receptor expression was examined in astrocytes in low-density and non-dividing (confluent) cultures from the cerebral cortex, hippocampus, cerebellum, and striatum of 1-day-old mice. Mu, delta, and kappa opioid receptor expression was assessed in individual cells immunocytochemically, by using flow cytometry, and functionally by examining agonist-induced changes in intracellular calcium ([Ca2+]i). Significant spatial and temporal differences were evident in the pattern of expression of mu, delta, and kappa receptors among astrocytes. In low-density cultures, greater proportions of astrocytes expressed mu-opioid receptor immunoreactivity in the cerebral cortex and hippocampus (26-34%) than in the cerebellum or striatum (7-12%). At confluence, a greater percentage of astrocytes in cerebellar (26%) and striatal (30%) cultures expressed mu-immunoreactivity. Fewer astrocytes possessed delta-immunoreactivity in low-density striatal cultures (8%) compared to other regions (16-22%). The proportion of delta receptor-expressing astrocytes declined in the cerebellum but increased in the hippocampus. Kappa-opioid receptors were uniformly expressed by 27-34% of astrocytes from all regions, except in cortical cultures, where the proportion of kappa expressing cells was 38% at low-density and decreased to 22% at confluence. Selective mu (PLO 17; H-Tyr-Pro-Phe (N-Me) -D-Pro-NH2, delta ([D-Pen2, D-Pen5] enkephalin), or kappa (U50,488H; trans-(+/-)-3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl) cyclohexyl] benzeneacetamide methanesulfonate) opioid receptor agonists increased [Ca2+]i in subpopulations of astrocytes indicating the presence of functional receptors. Lastly, opioid receptor immunofluorescence varied during the cell division cycle. A greater proportion of astrocytes in the G2/M phase of the cell cycle were mu or delta receptor immunofluorescent than at G0/G1. When astrocytes were reversibly arrested in G1, significantly fewer cells expressed delta receptor immunofluorescence; however, upon reentry into the cell cycle immunofluorescent cells reappeared. In conclusion, opioid phenotype varies considerably among individual cultured astrocytes, and this diversity was determined by regional and developmental (age and cell cycle dependent) differences in the brain. These in vitro findings suggest astroglia contribute to regional and developmental idiosyncrasies in opioid function within the brain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9482211      PMCID: PMC4319791     

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  53 in total

1.  kappa-opioid receptor expression defines a phenotypically distinct subpopulation of astroglia: relationship to Ca2+ mobilization, development, and the antiproliferative effect of opioids.

Authors:  J A Gurwell; M J Duncan; K Maderspach; A Stiene-Martin; R P Elde; K F Hauser
Journal:  Brain Res       Date:  1996-10-21       Impact factor: 3.252

2.  The kappa-opioid receptor is primarily postsynaptic: combined immunohistochemical localization of the receptor and endogenous opioids.

Authors:  U Arvidsson; M Riedl; S Chakrabarti; L Vulchanova; J H Lee; A H Nakano; X Lin; H H Loh; P Y Law; M W Wessendorf
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

3.  Primary astroglial cultures derived from several rat brain regions differentially express mu, delta and kappa opioid receptor mRNA.

Authors:  B B Ruzicka; C A Fox; R C Thompson; F Meng; S J Watson; H Akil
Journal:  Brain Res Mol Brain Res       Date:  1995-12-28

4.  Glial growth is regulated by agonists selective for multiple opioid receptor types in vitro.

Authors:  A Stiene-Martin; K F Hauser
Journal:  J Neurosci Res       Date:  1991-08       Impact factor: 4.164

5.  Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord.

Authors:  U Arvidsson; M Riedl; S Chakrabarti; J H Lee; A H Nakano; R J Dado; H H Loh; P Y Law; M W Wessendorf; R Elde
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

6.  Opioid-induced inhibition of voltage-gated calcium channels parallels expression of omega-conotoxin-sensitive channel subtype during differentiation of NG108-15 cells.

Authors:  W Jin; N M Lee; H H Loh; S A Thayer
Journal:  Brain Res       Date:  1993-04-02       Impact factor: 3.252

7.  Simultaneous DNA content and cell-surface immunofluorescence analysis.

Authors:  P P Brons; P E Van Erp; A H Pennings
Journal:  Methods Cell Biol       Date:  1994       Impact factor: 1.441

8.  Developmental expression of the proenkephalin and prosomatostatin genes in cultured cortical and cerebellar astrocytes.

Authors:  H Shinoda; A M Marini; J P Schwartz
Journal:  Brain Res Dev Brain Res       Date:  1992-06-19

9.  Opioids mobilize calcium from inositol 1,4,5-trisphosphate-sensitive stores in NG108-15 cells.

Authors:  W Jin; N M Lee; H H Loh; S A Thayer
Journal:  J Neurosci       Date:  1994-04       Impact factor: 6.167

10.  The regulation of proenkephalin expression in a distinct population of glial cells.

Authors:  M H Melner; K G Low; R G Allen; C P Nielsen; S L Young; R P Saneto
Journal:  EMBO J       Date:  1990-03       Impact factor: 11.598

View more
  48 in total

Review 1.  Selective vulnerability of cerebellar granule neuroblasts and their progeny to drugs with abuse liability.

Authors:  Kurt F Hauser; Valeriya K Khurdayan; Robin J Goody; Avindra Nath; Alois Saria; James R Pauly
Journal:  Cerebellum       Date:  2003       Impact factor: 3.847

2.  CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates.

Authors:  Nazira El-Hage; Guanghan Wu; Jayakrishna Ambati; Annadora J Bruce-Keller; Pamela E Knapp; Kurt F Hauser
Journal:  J Neuroimmunol       Date:  2006-07-10       Impact factor: 3.478

3.  Cell-specific actions of HIV-Tat and morphine on opioid receptor expression in glia.

Authors:  Jadwiga Turchan-Cholewo; Filomena O Dimayuga; Qunxing Ding; Jeffrey N Keller; Kurt F Hauser; Pamela E Knapp; Annadora J Bruce-Keller
Journal:  J Neurosci Res       Date:  2008-07       Impact factor: 4.164

4.  Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation.

Authors:  Jadwiga Turchan-Cholewo; Filomena O Dimayuga; Sunita Gupta; Jeffrey N Keller; Pamela E Knapp; Kurt F Hauser; Annadora J Bruce-Keller
Journal:  J Neurochem       Date:  2008-11-19       Impact factor: 5.372

5.  HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity.

Authors:  Crystal R Leibrand; Jason J Paris; Austin M Jones; Quamrun N Masuda; Matthew S Halquist; Woong-Ki Kim; Pamela E Knapp; Angela D M Kashuba; Kurt F Hauser; MaryPeace McRae
Journal:  J Neurovirol       Date:  2019-05-17       Impact factor: 2.643

6.  The opioid antagonist, beta-funaltrexamine, inhibits chemokine expression in human astroglial cells.

Authors:  Randall L Davis; Daniel J Buck; Neda Saffarian; Craig W Stevens
Journal:  J Neuroimmunol       Date:  2007-05-01       Impact factor: 3.478

7.  Glial-restricted precursors: patterns of expression of opioid receptors and relationship to human immunodeficiency virus-1 Tat and morphine susceptibility in vitro.

Authors:  S K Buch; V K Khurdayan; S E Lutz; P E Knapp; N El-Hage; K F Hauser
Journal:  Neuroscience       Date:  2007-05-02       Impact factor: 3.590

8.  CCL5/RANTES gene deletion attenuates opioid-induced increases in glial CCL2/MCP-1 immunoreactivity and activation in HIV-1 Tat-exposed mice.

Authors:  Nazira El-Hage; Annadora J Bruce-Keller; Pamela E Knapp; Kurt F Hauser
Journal:  J Neuroimmune Pharmacol       Date:  2008-09-25       Impact factor: 4.147

Review 9.  Diversity and Specificity of Astrocyte-neuron Communication.

Authors:  Caitlin A Durkee; Alfonso Araque
Journal:  Neuroscience       Date:  2018-11-17       Impact factor: 3.590

10.  Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity.

Authors:  Jianren Mao; Backil Sung; Ru-Rong Ji; Grewo Lim
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.